ArticleCancer discovery2021
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05257551 (Tempus SCLC Observational Study), which is not on this map. Cited by 165 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed, 1 pooled it
12.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tempus SCLC Observational Study: A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays
Who cites it
165 citing papers in PubMed, 1 synthesis or guideline pooled it, 199 citations in OpenAlex.
- A multiplexed in vivo approach to identify driver genes in small cell lung cancer.Cell reports · 2023Pooled it
- Trial
- NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING.The Journal of clinical investigation · 2025Trial
- A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.Molecular cancer · 2024Trial
- Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023Trial
- Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation.The Journal of clinical investigation · 2026Article
- AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer.Journal for immunotherapy of cancer · 2026Article
- Reprogramming resistance in advanced lung cancer: epigenetic modulation to restore therapeutic vulnerability.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Survival trends in extensive-stage small cell lung cancer in the pre-immunotherapy and immunotherapy eras: a population-based SEER study.Journal of thoracic disease · 2026Article
- A targetable dependency on nonsense-mediated decay for cellular homeostasis and immune control in small cell lung cancer.Molecular cancer · 2026Article
- cGAS-STING pathway activation drives the cold-to-hot tumor transition and sensitizes immunotherapy.Cancer biology & medicine · 2026Review
- Emerging Therapeutic Strategies in Small-Cell Lung Cancer: From Adaptive Resistance to Precision Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Epigenetics in lung cancer precision medicine: from bench to bedside-a narrative review.Translational lung cancer research · 2026Review
- [Expert Consensus on Immunotherapy for Extensive-stage Small Cell Lung Cancer Based on Molecular Subtyping].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Research progress on immune microenvironment and biomarkers of small cell lung cancer.Journal of thoracic disease · 2026Review
- Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity.Cancer cell · 2026Article
- PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer.Nature communications · 2026Article
- cGAS-STING pathway in lung cancer and emerging therapeutic approaches.Drug discovery today · 2026Review
- TAF1 Suppresses MHC-I Expression and Correlates with Poor Immunotherapy Response in Small Cell Lung Cancer.Biomedicines · 2026Article
105 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors at 7 institutions in 4 countries.
Navin R Mahadevan *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Erik H Knelson *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-4087-2017
Jacquelyn O WolffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Amir VajdiDepartment of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-8271-8566
Maria SaigíDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-5815-5388
Marco CampisiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-9288-5285
Deli HongDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Tran C ThaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Brandon PielDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Saemi HanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Bruce B ReinholdLaboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jonathan S Duke-CohanLaboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-9478-9609
Michael J PoitrasBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Luke J TausBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-0512-2536
Patrick H LizotteBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-9510-0036
Andrew PortellBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-0757-909X
Victor QuadrosDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-4054-8591
Alison D SantucciDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Takahiko MurayamaBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.ORCID 0000-0003-0764-8646
Israel CañadasBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.ORCID 0000-0001-6474-711X
Shunsuke KitajimaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Aoi AkitsuLaboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Maya FridrikhDepartment of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Hideo WatanabeDepartment of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-6017-6361
Brendan ReardonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Prafulla C GokhaleBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Cloud P PaweletzBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Mark M AwadDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Ana LakoTranslational Pathology, Bristol Myers Squibb, Trenton, New Jersey.
Xi-Tao WangTranslational Pathology, Bristol Myers Squibb, Trenton, New Jersey.
Benjamin ChenTranslational Pathology, Bristol Myers Squibb, Trenton, New Jersey.
Fangxin HongDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Lynette M ShollDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-9532-9735
Michael Y TolstorukovDepartment of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kathleen PfaffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Pasi A JänneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Evisa GjiniTranslational Pathology, Bristol Myers Squibb, Trenton, New Jersey.ORCID 0000-0002-6951-9279
Robin EdwardsTranslational Pathology, Bristol Myers Squibb, Trenton, New Jersey.
Scott RodigDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Ellis L ReinherzLaboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-1048-5526
Matthew G OserDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. david_barbie@dfci.harvard.edu matthew_oser@dfci.harvard.edu.
David A BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. david_barbie@dfci.harvard.edu matthew_oser@dfci.harvard.edu.
Dana-Farber Cancer Institute · USBristol-Myers Squibb (Germany) · DEBrigham and Women's Hospital · USFox Chase Cancer Center · USIcahn School of Medicine at Mount Sinai · USHarvard University · USPolitecnico di Torino · IT
Funding
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI A. Heather Eliassen · 1985 to 2026
$330.6MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MVASCULAR, PULMONARY AND RENAL INJURYT32HL007627 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GIMBRONE, MICHAEL A, MITCHELL, RICHARD N · 1985 to 2019
$12.7MTargeting the cytokine circuitry of KRAS-driven lung cancerR01CA190394 · NCI · DANA-FARBER CANCER INST · PI David A Barbie · 2015 to 2026
$4.5MIntegrative Bioengineering of Heart, Vessels, and BloodT32HL105373 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHIEN, SHU, INTAGLIETTA, MARCOS · 2010 to 2019
$3.6MDevelopment of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint BlockadeU01CA214381 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BARBIE, DAVID A, KAMM, ROGER D · 2017 to 2021
$3.5MOncopathology Training ProgramT32CA251062 · NCI · DANA-FARBER CANCER INST · PI JON C. ASTER, KATHLEEN H BURNS · 2020 to 2026
$2.4MBig Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0MTransforming Genomics with 5 PB Big Omics Data Engine Cray CS300-AC SupercomputerS10OD018522 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2014 to 2014
$1.9MNew Therapeutic Targets in Small Cell Lung Cancer that are Epistatic or Synthetic Lethal with pRB LossK08CA222657 · NCI · DANA-FARBER CANCER INST · PI OSER, MATTHEW GILBERT · 2017 to 2021
$886kNCI NIH HHS K08 CA222657NCI NIH HHS P30 CA006516NCI NIH HHS R01 CA190394NCI NIH HHS T32 CA009172NCI NIH HHS T32 CA251062NCI NIH HHS U01 CA214381NHLBI NIH HHS T32 HL007627NHLBI NIH HHS T32 HL105373NIH HHS S10 OD018522NIH HHS S10 OD026880
Abstract
Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. SCLC also exhibits cellular plasticity, which could influence its immunobiology. Here we discover that a distinct subset of SCLC uniquely upregulates MHC I, enriching for durable ICB benefit.
Indexed as
Cell PlasticityAnimalsCohort StudiesDisease Models, AnimalElectronic Health RecordsHumansLung NeoplasmsMiceSmall Cell Lung Carcinoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05257551ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.